experi
anim
demonstr
lung
transplant
technic
possibl
dr
jame
hardi
perform
first
human
lung
transplant
recipi
surviv
day
ultim
succumb
renal
failur
malnutrit
multipl
attempt
lung
transplant
fail
reject
complic
bronchial
anastomosi
improv
immunosuppress
especi
introduct
cyclosporin
enhanc
surgic
techniqu
led
renew
interest
organ
transplant
receiv
first
success
transplant
idiopath
pulmonari
arteri
hypertens
ipah
surviv
year
procedur
two
year
later
first
success
singl
lung
transplant
idiopath
pulmonari
fibrosi
ipf
report
first
doubl
lung
transplant
emphysema
perform
follow
year
number
lung
transplant
rapidli
increas
oper
becam
accept
treatment
endstag
lung
diseas
today
four
major
surgic
approach
lung
transplant
singl
bilater
lung
transplant
blt
transplant
transplant
lobe
lung
live
donor
lung
transplant
procedur
report
worldwid
registri
intern
societi
heart
lung
transplant
ishlt
adult
highest
number
year
year
lung
transplant
report
children
major
adolesc
year
old
although
number
singl
lung
transplant
rel
stabl
blt
continu
increas
within
past
year
fact
blt
common
lung
transplant
procedur
perform
lung
transplant
procedur
larg
due
transplant
cystic
fibrosi
chronic
obstruct
lung
diseaseemphysema
made
blt
mean
age
transplant
recipi
consist
increas
sinc
rise
time
high
year
common
indic
lung
transplant
adult
chronic
obstruct
pulmonari
diseas
copd
emphysema
ipf
cystic
fibrosi
antitrypsin
defici
emphysema
aat
see
tabl
indic
pediatr
lung
transplant
vari
age
see
tabl
children
year
old
cystic
fibrosi
common
indic
follow
ipah
contrast
infant
preschool
children
lung
transplant
usual
perform
ipah
congenit
heart
diseas
idiopath
interstiti
pneumon
surfact
protein
defici
wellselect
patient
system
diseas
sarcoidosi
lymphangioleiomyomatosi
pulmonari
langerhan
cell
histiocytosi
also
satisfactori
result
lung
transplant
select
patient
scleroderma
multipl
case
incident
even
stage
iiia
nonsmal
cell
carcinoma
excis
nativ
lung
transplant
recipi
report
although
one
patient
stage
iiia
poorli
differenti
squamou
cell
carcinoma
die
month
transplant
neoplast
thromboembolu
patient
carcinoma
gener
free
recurr
current
patient
near
endstag
lung
diseas
limit
life
expect
consid
lung
transplant
howev
sinc
lung
transplant
rapidli
evolv
field
hard
fast
rule
may
transplant
choos
transplant
procedur
sever
issu
consid
includ
shortag
organ
donor
origin
diseas
center
experi
graft
patient
surviv
gener
guidelin
select
procedur
propos
base
natur
underli
lung
diseas
blt
mandatori
cystic
fibrosi
procedur
also
becom
popular
indic
aat
copd
ipf
ipah
singlelung
transplant
usual
perform
patient
restrict
fibrot
lung
diseas
eisenmeng
syndrom
repar
cardiac
anomali
older
patient
copd
transplant
consid
patient
eisenmeng
syndrom
irrepar
cardiac
defect
pulmonari
hypertens
cor
pulmonal
endstag
lung
diseas
concurr
sever
cardiac
diseas
transplant
lobe
live
donor
recent
develop
techniqu
involv
bilater
implant
lower
lobe
usual
two
blood
live
donor
procedur
perform
patient
cystic
fibrosi
although
indic
recent
broaden
function
surviv
outcom
similar
achiev
convent
transplant
cadaver
lung
donat
lobe
decreas
donor
lung
volum
averag
approxim
associ
longterm
function
limit
factor
recipi
must
taken
consider
individu
basi
includ
ventil
depend
previou
cardiothorac
surgeri
preexist
medic
condit
eg
hypertens
diabet
mellitu
osteoporosi
sinc
posttransplant
medic
regimen
worsen
ill
sever
coronari
arteri
diseas
contraind
lung
transplant
howev
coronari
arteri
bypass
graft
time
lung
transplant
perform
reason
good
outcom
center
although
less
invas
preoper
intervent
percutan
translumin
coronari
angioplasti
stent
prefer
although
donor
select
criteria
may
vari
amongst
center
gener
accept
donor
criteria
includ
age
donor
year
lung
transplant
year
transplant
averag
donor
age
year
donor
criteria
includ
absenc
sever
chest
trauma
infect
prolong
cardiac
arrest
transplant
minim
pulmonari
secret
neg
screen
hiv
hepat
c
hepat
b
blood
type
abo
compat
close
match
lung
size
donor
recipi
mmhg
fraction
inspir
oxygen
clear
chest
radiograph
histori
malign
neoplasm
also
requir
transplant
center
use
lung
cytomegaloviru
cmv
posit
donor
transplant
cmvneg
donor
given
adequ
postop
cmv
prophylaxi
current
techniqu
satisfactori
graft
function
obtain
ischem
interv
long
h
pulmonari
preserv
system
heparin
donor
hypotherm
flush
perfus
allograft
commonli
use
clinic
practic
flush
solut
administ
temperatur
topic
cool
carri
fill
pleural
caviti
ice
crystalloid
solut
harvest
lung
immers
crystalloid
solut
pack
ice
transport
temperatur
infus
transport
perform
activ
ventil
static
inflat
respect
acut
chronic
alloreact
injuri
donor
lung
affect
vasculatur
airway
usual
reject
evalu
transbronchi
biopsi
see
sect
rare
occas
wedg
biopsi
perform
specimen
might
includ
explant
retranspl
autopsi
specimen
acut
reject
character
perivascular
mononuclear
cell
infiltr
may
accompani
subendotheli
chronic
inflamm
eg
endotheli
intim
also
lymphocyt
bronchiol
contrast
chronic
reject
manifest
fibrou
scar
involv
bronchiol
sometim
associ
acceler
fibrointim
chang
affect
pulmonari
arteri
vein
presenc
presum
irrevers
dens
eosinophil
hyalin
fibrosi
airway
vessel
remain
key
histolog
discrimin
acut
chronic
reject
lung
histolog
chang
divid
grade
base
intens
cellular
infiltr
presenc
absenc
fibrosi
hyperacut
reject
occur
within
minut
hour
newli
transplant
organ
begin
perfus
type
ii
hypersensit
reaction
mediat
preexist
antibodi
abo
blood
group
human
leukocyt
antigen
hla
class
antigen
graft
vascular
endotheli
cell
preexist
antibodi
result
previou
pregnanc
blood
transfus
previou
transplant
antibodi
bind
provok
complement
cytokin
activ
lead
endotheli
cell
damag
platelet
activ
subsequ
vascular
thrombosi
graft
destruct
outcom
usual
fatal
lung
hyperacut
reject
grossli
present
edema
cyanosi
graft
histolog
platelet
thrombi
neutrophil
infiltr
fibrin
thrombi
necrosi
vessel
wall
morpholog
featur
diffus
alveolar
damag
dad
observ
although
hyperacut
reject
wellknown
complic
kidney
heart
transplant
lung
transplant
appear
rather
rare
five
case
report
one
patient
report
present
sever
hypoxia
high
fever
hemodynam
instabl
develop
acut
renal
failur
h
complet
anastomos
chest
radiograph
display
complet
opacifi
left
lung
homogen
infiltr
bronchoscopi
reveal
abund
pink
frothi
fluid
drain
allograft
mean
pulmonari
arteri
pressur
increas
mmhg
patient
die
h
later
autopsi
vascular
bronchial
anastomos
appear
patent
without
sign
injuri
transplant
lung
show
red
hepat
firm
consist
microscop
sign
acut
lung
injuri
evid
although
pretranspl
panelreact
antibodi
pra
neg
flowcytometri
reveal
reactiv
hla
class
ii
respect
detect
among
preform
antibodi
three
report
patient
hyperacut
reject
die
within
h
day
transplant
although
three
five
report
patient
pretranspl
pra
neg
crossmatch
posit
case
common
identifi
antibodi
collect
although
hyperacut
reject
rare
lung
transplant
one
keep
reaction
mind
given
falseneg
pra
may
occur
pretransplant
cross
match
often
possibl
acut
reject
host
respons
recognit
graft
foreign
patient
develop
least
one
episod
acut
reject
within
first
week
follow
transplant
typic
first
day
patient
experienc
least
one
episod
first
year
oblit
bronchiol
ob
common
late
caus
mortal
morbid
lung
transplant
occur
year
year
patient
surviv
least
day
also
signific
neg
impact
qualiti
life
paramet
risk
acut
reject
includ
hla
mismatch
type
immunosuppress
infect
recipi
factor
gener
thought
intens
host
alloimmun
respons
relat
recipi
recognit
differ
donor
hla
antigen
process
drive
acut
lung
allograft
reject
higher
degre
mismatch
increas
risk
acut
reject
howev
effect
consist
across
hla
loci
studi
mismatch
hladr
hlab
hlaa
loci
well
combin
three
loci
appear
import
addit
ishlt
registri
found
correl
hla
mismatch
surviv
thu
hla
mismatch
donor
recipi
like
contribut
immunolog
basi
acut
reject
difficult
discern
mismatch
particular
locu
differ
degre
mismatch
significantli
alter
overal
risk
acut
reject
viral
infect
thought
modul
immun
system
heighten
alloreact
inde
high
incid
acut
reject
found
lung
transplant
recipi
communityacquir
respiratori
tract
infect
human
influenza
viru
respiratori
syncyti
viru
rsv
rhinoviru
coronaviru
parainfluenzaviru
although
cmv
consid
potenti
risk
factor
ob
studi
directli
link
cmv
infect
cmv
prophylaxi
strategi
acut
reject
inconsist
one
studi
chlamydia
pneumonia
infect
link
develop
acut
reject
ob
sever
host
genet
characterist
suggest
modul
acut
lung
reject
instanc
genotyp
lead
increas
product
may
protect
acut
reject
multidrugresist
genotyp
appear
predispos
persist
acut
reject
resist
immunosuppress
treatment
effect
age
acut
reject
appear
bimod
lowest
incid
acut
reject
infanc
age
increas
risk
childhood
compar
adulthood
incid
acut
reject
older
lung
transplant
recipi
age
higher
seem
chang
fact
increas
rate
infect
older
lung
transplant
recipi
thought
contribut
increas
mortal
detect
one
center
argu
reduc
immunosuppress
patient
clinic
cours
acut
reject
variabl
patient
acut
reject
might
present
dyspnea
fever
leukocytosi
widen
alveolararteri
oxygen
gradient
highergrad
reject
appear
caus
sever
symptom
lead
acut
respiratori
distress
patient
reject
pulmonari
function
test
may
show
decreas
forc
expiratori
volum
vital
capac
vc
although
spirometri
sensit
greater
detect
infect
reject
grade
higher
differenti
two
use
spirometri
diminish
singl
lung
transplant
recipi
contralater
nativ
lung
dysfunct
confound
pulmonari
function
test
result
pulmonari
function
test
therefor
use
adjunct
clinic
evalu
although
approxim
half
case
acut
reject
find
chest
radiograph
normal
chest
radiograph
may
reveal
illdefin
perihilar
lower
lobe
opac
along
septal
line
pleural
effus
find
ct
scan
might
includ
groundglass
opac
septal
thicken
volum
loss
nodul
consolid
pleural
effus
infiltr
observ
imag
studi
first
week
lung
transplant
usual
caus
reimplant
respons
ie
reperfus
edema
persist
infiltr
beyond
first
week
suggest
acut
reject
infect
howev
although
earli
small
studi
attempt
demonstr
use
chest
xray
chest
ct
scan
diagnosi
reject
recent
data
show
low
sensit
acut
reject
low
discriminatori
valu
reject
process
exhal
nitric
oxid
also
attract
marker
lung
injuri
correl
lymphocyt
bronchiol
acut
reject
furthermor
studi
inert
ga
singl
breath
washout
slope
alveolar
plateau
helium
sensit
acut
reject
although
lung
transplant
come
age
develop
ob
remain
biggest
hurdl
prevent
longterm
surviv
mani
patient
low
sensit
specif
ob
remain
difficult
prove
patholog
transbronchi
biopsi
consequ
clinic
definit
call
bronchiol
obliteran
syndrom
bo
propos
base
pulmonari
function
criteria
initi
evolut
recent
midexpiratori
flow
rate
onset
bossymptom
usual
insidi
progress
exert
dyspnea
often
accompani
cough
may
dri
product
incid
bo
highest
first
year
follow
lung
transplant
howev
risk
bo
increas
year
lung
transplant
procedur
remain
lead
caus
morbid
death
lung
transplant
account
late
mortal
patient
affect
condit
year
transplant
discuss
acut
immunolog
event
acut
reject
may
trigger
onset
ob
howev
nonalloimmun
injuri
respiratori
tract
infect
cmv
noncmv
viral
infect
increasingli
recogn
also
import
impact
develop
ob
fact
cmv
pneumon
affect
lung
transplant
recipi
despit
treatment
increas
risk
ob
death
earli
detect
ob
preclin
stage
ideal
aggress
attempt
made
prevent
fulli
develop
syndrom
howev
date
particular
marker
indic
ob
either
peripher
blood
bronchoalveolar
lavag
bal
fluid
predict
risk
diseas
associ
chronic
aspir
ob
transplant
also
observ
high
frequenc
gastroesophag
reflux
result
aspir
follow
lung
transplant
instanc
one
studi
describ
gastrointestin
complic
includ
gastroesophag
reflux
patient
underw
lung
transplant
lead
increas
acut
reject
exacerb
alloimmun
respons
aspir
gastric
content
might
act
independ
alloimmun
respons
promot
allograft
injuri
develop
ob
experi
rat
substanti
associ
chronic
aspir
ob
despit
common
clinic
impress
lymphocyt
pleural
effus
hallmark
acut
reject
publish
data
inconclus
collect
although
present
patient
sever
ancillari
studi
might
suggest
transplant
reject
process
tissu
diagnosi
necessari
definit
diagnosi
ishlt
sponsor
lung
reject
studi
group
lrsg
workshop
develop
work
formul
diagnosi
lung
reject
transbronchi
biopsi
propos
grade
scheme
found
wide
accept
due
develop
field
experi
use
lrsg
remet
twice
sinc
assess
merit
grade
scheme
revis
publish
respect
grade
scheme
strictli
patholog
consid
clinic
paramet
due
overlap
histolog
featur
acut
reject
infect
grade
scheme
reli
absenc
concurr
infect
recent
classif
lung
allograft
biopsi
ishlt
revis
consensu
classif
allograft
reject
see
tabl
classif
revis
ishlt
consensu
classif
signific
chang
grade
acut
reject
latest
classif
acknowledg
minim
acut
reject
sole
high
power
diagnosi
also
recogn
low
power
adequ
alveol
biopsi
grade
system
small
airway
reject
grade
fourtier
system
respect
see
tabl
classif
consolid
low
grade
high
grade
small
airway
inflamm
make
evalu
easier
r
behind
denot
revis
classif
chronic
airway
reject
divid
activ
inact
anymor
present
present
differ
classif
chronic
vascular
reject
classif
attempt
made
accur
distinguish
grade
reject
sinc
treatment
larg
depend
histolog
grade
furthermor
effort
made
review
report
previou
biopsi
comment
whether
reject
ongo
resolv
although
gener
patient
grade
biopsi
receiv
increas
immunosuppress
surveil
might
intensifi
time
next
biopsi
shorten
contrast
biopsi
patient
receiv
increas
immunosuppress
grade
patient
treat
similar
receiv
immunosuppress
inter
intraobserv
variabl
grade
impact
treatment
outcom
studi
evalu
inter
intraobserv
variabl
grade
scheme
two
studi
found
rel
good
interobserv
agreement
agrad
kappa
could
replic
anoth
studi
kappa
spite
dichotom
agrad
vs
intraobserv
agreement
acut
reject
found
good
kappa
valu
infect
complic
diagnosi
acut
reject
viral
infect
particular
caus
mononuclear
inflamm
addit
alveolar
damag
macrophag
fibrin
accumul
found
present
transbronchi
biopsi
first
month
transplant
increas
interobserv
pathologist
discord
therefor
gener
lrsg
recommend
grade
reject
exclus
infect
contrast
agrad
interobserv
variabl
grade
airway
inflamm
bgrade
fair
kappa
app
reason
lrsg
simplifi
bgrade
two
possibl
grade
nomenclatur
use
grade
noncartilagen
small
airway
rigor
exclus
infect
eosinophil
accompani
acut
lung
reject
recogn
ishlt
classif
high
grade
reject
grade
presenc
eosinophil
suggest
risk
factor
bo
small
singlecent
studi
furthermor
high
proport
b
cell
shown
accompani
steroidresist
reject
lung
transplant
patient
mechan
b
cell
contribut
refractori
reject
entir
clear
although
may
reflect
ongo
humor
reject
perhap
explain
diminish
respons
standard
immunosuppress
mast
cell
identifi
acut
reject
biopsi
increas
agrad
role
elucid
reject
chronic
airway
inflamm
distinguish
bronchiolar
associ
lymphoid
tissu
balt
balt
found
vicin
airway
usual
contain
black
anthracot
pigment
present
rather
nodular
collect
chronic
inflammatori
cell
surround
vessel
grade
normal
pulmonari
parenchyma
present
scatter
infrequ
blood
vessel
particularli
venul
alveol
lung
parenchyma
surround
rel
thin
chronic
mononuclear
infiltr
see
fig
lymphocyt
rim
rather
small
spill
adjac
interstitium
endotheli
eosinophil
absent
although
previou
classif
system
comment
certain
number
lymphocyt
layer
current
ishlt
classif
requir
complet
rim
vessel
lymphocyt
adequ
alveol
artifactfre
specimen
lymphocyt
infiltr
might
detect
low
magnif
although
mild
acut
reject
perivascular
infiltr
lymphocyt
essenti
confin
perivascular
adventitia
without
infiltr
interstitium
layer
lymphocyt
surround
vessel
lymphocyt
might
focal
minim
spill
adjac
interstitium
see
fig
frequent
perivascular
mononuclear
infiltr
seen
surround
venul
arteriol
readili
recogniz
low
magnif
infiltr
usual
consist
mixtur
small
round
lymphocyt
activ
lymphocyt
plasmacytoid
lymphocyt
macrophag
eosinophil
frequent
subendotheli
infiltr
mononuclear
cell
may
associ
hyperplast
regen
chang
endothelium
ie
endotheli
concurr
lymphocyt
bronchiol
may
seen
associ
mild
acut
reject
grade
acut
reject
show
easili
recogniz
cuff
venul
arteriol
dens
perivascular
mononuclear
cell
infiltr
commonli
associ
endotheli
see
fig
eosinophil
even
occasion
neutrophil
common
grade
defin
extens
inflammatori
cell
infiltr
perivascular
peribronchiolar
alveolar
septa
broaden
interalveolar
septa
airspac
associ
collect
intraalveolar
macrophag
zone
septal
infiltr
type
ii
pneumocyt
hyperplasia
histolog
featur
acut
lung
injuri
may
becom
appar
sever
reject
diffus
perivascular
interstiti
air
space
infiltr
mononuclear
cell
promin
alveolar
pneumocyt
damag
endotheli
see
fig
may
associ
intraalveolar
necrot
epitheli
cell
macrophag
eosinophil
hemorrhag
neutrophil
usual
evid
acut
lung
injuri
form
organ
pneumonia
hyalin
membran
parenchym
necrosi
infarct
necrot
vascul
might
identifi
howev
featur
evid
surgic
rather
transbronchi
lung
biopsi
note
paradox
diminut
perivascular
infiltr
occur
cell
extend
alveolar
septa
space
admix
macrophag
grade
sometim
difficult
distinguish
infecti
process
harvestreperfus
injuri
drug
toxic
howev
presenc
perivascular
inflamm
help
establish
diagnosi
small
airway
appear
unremark
without
evid
bronchiolar
inflamm
low
grade
inflamm
character
lymphocyt
within
submucosa
bronchiol
see
fig
lymphocyt
infiltr
infrequ
scatter
form
circumferenti
band
howev
intraepitheli
lymphocyt
infiltr
present
although
occasion
eosinophil
may
seen
within
submucosa
evid
epitheli
damag
neutrophil
necrosi
ulcer
signific
amount
nuclear
debri
grade
combin
replac
work
formul
grade
high
grade
small
airway
inflamm
mark
lymphocyt
infiltr
airway
epithelium
airway
wall
mononuclear
cell
submucosa
appear
larger
activ
greater
number
eosinophil
plasmacytoid
cell
addit
evid
epitheli
damag
includ
necrosi
metaplasia
mark
intraepitheli
lymphocyt
infiltr
sever
form
high
grade
airway
inflamm
associ
epitheli
ulcer
fibrinopurul
exud
cellular
debri
neutrophil
import
exclud
infecti
process
grade
chang
ungrad
due
sampl
problem
infect
tangenti
cut
artifact
etc
small
airway
appear
similar
size
accompani
arteri
rag
inner
surfac
fibrosi
present
narrow
airway
due
fibrosi
airway
wall
seen
fibrosi
usual
eccentr
see
fig
ob
may
manifest
histopatholog
spectrum
chang
depend
acut
process
degre
organ
amount
accompani
inflamm
acut
phase
usual
loos
myxoid
granul
tissu
variabl
number
inflammatori
cell
fill
partial
obstruct
airway
lumen
resembl
organ
pneumonia
later
phase
ob
may
consist
eccentr
occasion
confluent
plaqu
dens
hyalin
collagen
appli
wall
bronchiol
metaplast
squamou
cuboid
epithelium
may
cover
bronchiolar
scar
airway
slitlik
lumen
may
remain
result
confluent
submucos
scar
intralumin
polyp
scar
tissu
capillari
suppli
intralumin
mass
collagen
occasion
promin
sever
case
bronchiolar
lumen
entir
occlud
dens
scar
tissu
recogniz
aid
elast
stain
locat
adjac
arteri
presenc
residu
circumferenti
smooth
muscl
later
phase
inflamm
may
minim
usual
scar
process
confin
exclus
respiratori
bronchiol
termin
bronchiol
although
may
occasion
involv
adjac
alveoli
pulmonari
arteri
appear
similar
size
accompani
airway
intima
slender
media
thicken
chronic
vascular
reject
rare
identifi
biopsi
sinc
usual
lack
vessel
suffici
size
wedg
biopsi
explant
autopsi
materi
may
reveal
typic
case
pulmonari
arteri
often
vein
thicken
fibrointim
connect
tissu
see
fig
also
thicken
usual
concentr
chronic
vascular
reject
may
patchi
typic
involv
smaller
vascular
arteri
vein
earli
stage
chronic
vascular
reject
intim
prolifer
occur
lumin
aspect
intact
elast
lamella
subsequ
intern
elastica
may
becom
fragment
discontinu
occasion
underli
muscular
wall
becom
thin
approxim
half
report
case
concurr
endovascul
observ
process
similar
pulmonari
vein
although
intim
deposit
may
less
cellular
waxi
eosinophil
sclerot
chronic
vascular
reject
distinguish
recan
thrombi
unlik
situat
heart
transplant
recipi
chronic
vascular
reject
lung
transplant
result
graft
loss
howev
patient
develop
pulmonari
hypertens
particularli
bo
mimick
sever
acut
reject
includ
condit
might
present
acut
lung
injuri
dad
condit
includ
infect
drug
toxic
antibodi
mediat
reject
amr
harvestreperfus
injuri
therefor
care
slide
review
perivascular
inflamm
perform
stain
microorgan
includ
gomorigrocott
methenamin
silver
stain
gm
acid
fast
bacilli
afb
might
ad
care
search
viral
inclus
undertaken
although
perivascular
mononuclear
infiltr
help
identifi
reject
entir
specif
acut
reject
mani
condit
may
simul
mimic
alloreact
lung
injuri
differenti
diagnost
consider
includ
cmv
pneumon
pneumocysti
jiroveci
pneumonia
posttransplant
lymphoprolif
diseas
ptld
differenti
diagnosi
perivascular
interstiti
infiltr
includ
recurr
primari
diseas
amr
humor
reject
well
establish
solid
organ
transplant
origin
recogn
kidney
transplant
patient
present
acut
allograft
reject
antidonor
antibodi
poor
prognosi
amr
thought
due
circul
antibodi
either
preform
pregnanc
blood
transfus
previou
organ
transplant
aris
de
novo
transplant
due
hlamismatch
although
amr
increasingli
recogn
entiti
lung
transplant
still
investig
earli
observ
base
phenomenon
hyperacut
reject
preexist
donorspecif
antibodi
lead
complement
activ
rapid
graft
loss
later
recogn
lung
transplant
recipi
also
develop
antibodi
transplant
allograft
might
lead
amr
evid
suggest
amr
occur
donor
major
histocompat
mhc
antigen
although
endotheli
epitheli
antigen
express
lung
may
becom
antibodi
target
well
recent
develop
sensit
specif
solid
phase
flowcytometri
luminexbas
methodolog
allow
accur
detect
antibodi
specif
sensit
recipi
becom
clear
patient
previous
expect
present
preform
antihla
antibodi
immun
stimul
prior
infect
autoimmun
might
contribut
develop
antibodi
allomhc
patient
identifi
risk
factor
preexist
antibodi
react
donor
antigen
lead
immedi
graft
loss
hyperacut
reject
acceler
humor
reject
bo
furthermor
recent
studi
consist
demonstr
increas
incid
acut
reject
threefold
increas
one
studi
persist
reject
increas
bo
wors
overal
surviv
patient
antihla
antibodi
effect
appar
pretranspl
hla
sensit
develop
de
novo
antihla
donorspecif
antibodi
transplant
lung
transplant
recipi
presensit
hla
antigen
even
though
unaccept
antigen
avoid
virtual
crossmatch
patient
posit
pretranspl
pra
higher
risk
posttranspl
complic
posttranspl
pra
stay
stabl
increas
via
gener
either
donorspecif
nondonorspecif
antihla
antibodi
similarli
patient
neg
pra
screen
test
transplant
develop
de
novo
nondonorspecif
donorspecif
antihla
antibodi
transplant
mechan
antibodi
promot
lung
allograft
injuri
remain
poorli
understood
antibodi
bind
allomhc
endotheli
epitheli
target
lung
could
lead
activ
complement
cascad
complement
deposit
lead
endotheli
cell
injuri
product
proinflammmatori
molecul
recruit
inflammatori
cell
complement
independ
antibodymedi
mechan
also
induc
endotheli
cell
activ
without
cell
injuri
lead
increas
gene
express
subsequ
prolifer
demonstr
vitro
studi
antihla
antibodi
caus
prolifer
airway
epitheli
cell
well
produc
fibroblaststimul
growth
factor
potenti
contribut
gener
oblit
airway
lesion
recent
studi
attempt
evalu
immunoglobulin
ig
complement
deposit
subendotheli
space
septal
capillari
deposit
ig
complement
product
describ
associ
antihla
antibodi
well
allograft
dysfunct
bo
concept
specif
histopatholog
featur
associ
humor
reject
remain
controversi
lung
transplant
recent
studi
question
relat
complement
ig
stain
allograft
reject
other
demonstr
stain
occur
lung
transplant
recipi
nonalloimmun
lung
injuri
infect
primari
graft
dysfunct
pgd
evid
antihla
antibodi
differ
stain
techniqu
differ
laboratori
may
explain
inconsist
publish
data
ishlt
revis
consensu
classif
agre
upon
histopatholog
featur
might
specif
amr
lung
although
capillari
injurysmal
vessel
intim
might
rais
suspicion
amr
nonspecif
find
also
occur
sever
acut
reject
infect
harvestreperfus
injuri
furthermor
although
often
term
capillar
mention
ishlt
recommend
use
term
capillari
injuri
allow
broader
spectrum
morpholog
chang
vessel
includ
intim
whole
wall
thick
inflamm
neutrophil
infiltr
distinguish
neutrophil
margin
thrombosi
necrosi
furthermor
sign
dad
intraalveolar
hemorrhag
occur
amr
although
specif
given
lack
specif
histolog
find
amr
lung
transplant
multidisciplinari
approach
diagnosi
recommend
includ
follow
presenc
circul
antibodi
hla
antibodi
antiendotheli
antiepitheli
antibodi
focal
diffus
deposit
see
fig
histolog
featur
acut
lung
injuri
hemorrhag
dad
capillari
injuri
neutrophil
nuclear
debri
clinic
sign
graft
dysfunct
amr
clinic
immunopatholog
histolog
suspect
one
might
perform
immunostain
howev
stain
extrapol
kidney
heart
transplant
although
sever
studi
advoc
use
larg
scale
studi
valid
use
studi
extens
kidney
heart
transplant
identifi
use
adjunct
diagnosi
amr
organ
howev
lung
case
one
reason
difficulti
lung
rel
high
background
encount
immunohistochemistri
ihc
well
immunofluoresc
often
bind
elast
lamina
show
nonspecif
bind
stain
commonli
focal
therefor
sensit
specif
establish
yet
given
limit
sampl
size
transbronchi
biopsi
linear
continu
subendotheli
stain
capillari
arteriol
andor
venul
count
posit
ihc
also
specif
amr
also
seen
infect
harvestreperfus
injuri
even
sever
acut
reject
basic
process
associ
complement
activ
ihslt
recommend
time
regard
coexist
amr
acut
reject
although
clinic
evalu
patient
may
suggest
possibl
reject
tissu
evalu
necessari
definit
diagnosi
initi
investig
hesit
routin
util
transbronchi
biopsi
monitor
graft
thought
amount
tissu
obtain
would
small
make
definit
diagnosi
also
concern
pass
bronchoscop
anastomosi
howev
transbronchi
biopsi
routin
procedur
becom
gold
standard
evalu
graft
acut
chronic
reject
infect
possibl
recurr
diseas
sinc
current
surrog
marker
suffici
valid
mean
reproduc
identifi
patient
acut
reject
specif
serolog
marker
indic
reject
occur
lung
transplant
total
bal
fluid
cell
count
constantli
increas
even
period
evid
infect
reject
earli
posttransplant
period
first
week
domin
neutrophil
bal
fluid
total
cell
count
month
later
cell
count
normal
acut
reject
associ
elev
cell
activ
cell
trend
toward
increas
nk
cell
increas
b
cell
decreas
nk
cell
bal
nevertheless
studi
proven
bal
cellular
composit
adequ
sensit
specif
discrimin
reject
infect
small
studi
found
correl
acut
reject
elev
ifn
gamma
bal
recent
advantag
genom
offer
potenti
specif
mean
diagnos
reject
lung
transplant
pilot
studi
gene
express
bal
lung
transplant
recipi
found
gene
express
signatur
relat
tlymphocyt
function
cytotox
activ
neutrophil
degranul
correl
acut
reject
howev
studi
clinic
use
present
time
recent
publish
studi
heart
transplant
describ
use
peripher
blood
gene
express
profil
identifi
futur
risk
cardiac
allograft
reject
similar
studi
underway
lung
transplant
known
lung
allograft
reject
gene
express
observ
largo
studi
preliminari
data
almost
patient
similar
cargo
result
show
differenti
gene
express
lymphocyt
prime
neutrophil
homeostasi
pathway
vs
acut
lung
reject
test
may
hold
promis
noninvas
techniqu
monitor
statu
transplant
organ
anoth
studi
describ
mark
serum
elev
hepatocyt
growth
factor
hgf
lung
transplant
recipi
acut
reject
howev
smaller
elev
hgf
also
occur
lung
infect
addit
studi
need
valid
specif
sensit
hgf
acut
reject
conclus
although
promis
noninvas
techniqu
earli
studi
need
confirm
larger
studi
consid
widespread
clinic
use
therefor
microscop
tissu
evalu
remain
gold
standard
diagnos
reject
bronchoscopi
biopsi
postlung
transplant
gener
perform
clinic
suspicion
reject
infect
recurr
diseas
ptld
addit
mani
transplant
center
follow
protocol
biopsi
howev
pro
con
surveil
bronchoscopi
biopsi
still
debat
therefor
guidelin
establish
regard
time
postlung
transplant
surveil
bronchoscopi
biopsi
one
institut
report
surveil
biopsi
pediatr
lung
transplant
recipi
week
month
posttransplant
ration
surveil
biopsi
includ
occurr
clinic
silent
acut
reject
inadequ
surrog
marker
acut
reject
rel
low
risk
bronchoscopi
procedur
yield
acut
reject
transbronchi
biopsi
report
greater
studi
perform
surveil
transbronchi
biopsi
clinic
indic
followup
bronchoscopi
grade
higher
acut
reject
found
rel
high
percentag
asymptomat
patient
rang
silent
acut
reject
appear
common
within
first
month
transplant
month
month
year
rate
unsuspect
clinic
signific
infect
highest
month
posttransplant
rel
high
rate
also
detect
year
one
small
studi
question
benefit
perform
surveil
bronchoscopi
biopsi
suggest
benefit
outweigh
procedur
risk
studi
chang
manag
base
transbronchi
biopsi
bal
result
significantli
higher
clinic
indic
group
compar
surveil
group
mostli
relat
infect
interestingli
silent
acut
reject
episod
requir
treatment
detect
surveil
group
studi
collect
find
may
reflect
differ
program
oper
although
shown
transbronchi
biopsi
often
mean
reveal
silent
acut
reject
allograft
definit
evid
treatment
episod
posit
impact
surviv
prevent
bo
yet
demonstr
howev
base
link
acut
reject
develop
bo
surveil
transbronchi
biopsi
asymptomat
lung
transplant
recipi
becom
common
practic
mani
larg
lung
transplant
center
evid
suggest
patient
multipl
episod
low
grade
lesion
within
first
month
posttransplant
develop
earli
onset
bo
howev
differ
overal
surviv
patient
without
acut
reject
also
evid
reject
increas
risk
highergrad
subsequ
reject
find
solitari
perivascular
monocyt
infiltr
follow
worsen
acut
reject
four
untreat
patient
one
studi
treatment
solitari
infiltr
nine
patient
result
improv
reject
score
presenc
sever
lymphocyt
bronchiol
also
associ
increas
risk
bo
death
lung
transplant
independ
presenc
acut
reject
studi
surveil
transbronchi
biopsi
perform
week
posttransplant
time
symptom
followup
acut
reject
cmv
pneumonia
show
patient
develop
acut
small
airway
reject
within
first
year
transplant
risk
develop
bo
year
detect
lesion
ishlt
criteria
see
tabl
lesion
lesion
respect
studi
strongli
suggest
main
util
surveil
biopsi
may
use
lymphocyt
bronchiol
surrog
predictor
longterm
outcom
howev
impact
therapi
lymphocyt
bronchiol
yet
assess
although
complic
relat
bronchoscopi
occur
includ
small
risk
sever
complic
major
case
favor
outcom
advers
event
report
bronchoscopi
lung
transplant
recipi
includ
transient
hypoxemia
bleed
pneumothorax
arrhythmia
anesthesia
relat
complic
bronchoscopi
may
contribut
faster
deterior
one
patient
alreadi
critic
condit
howev
posttransplant
set
bronchoscopi
report
mortal
although
anecdot
report
death
relat
transbronchi
biopsi
ishlt
revis
consensu
classif
acut
allograft
reject
requir
evalu
least
five
piec
wellexpand
alveol
parenchyma
howev
bronchoscopist
may
need
submit
five
piec
provid
minimum
number
biopsi
may
improv
detect
ob
although
specif
number
small
airway
requir
ishlt
consensu
classif
exclud
diagnosi
gentl
agit
formalin
open
alveoli
may
improv
histolog
appear
fragment
histolog
examin
includ
three
level
paraffin
block
hematoxylin
eosin
h
e
stain
connect
tissu
stain
trichrom
verhoeffvan
gieson
vvg
stain
evalu
airway
presenc
submucos
fibrosi
essenti
diagnosi
ob
atherosclerosi
silver
stain
gm
perform
fungi
includ
pneumocysti
routin
mandat
ishlt
revis
consensu
classif
given
numer
microbiolog
serolog
molecular
techniqu
avail
diagnosi
opportunist
infect
bal
may
perform
time
biopsi
use
exclus
infect
current
clinic
role
diagnosi
acut
reject
see
bacteri
pneumonia
common
infect
follow
lung
transplant
occur
patient
first
year
transplant
highest
incid
first
month
posttransplant
see
fig
furthermor
bacteri
pneumonia
remain
major
infecti
complic
throughout
patient
life
donor
lung
affect
often
gramneg
organ
common
especi
enterobact
pseudomona
bronchiti
secondari
pseudomona
speci
staphylococcu
aureu
infect
also
observ
bacteri
pneumonia
typic
manifest
radiograph
lobar
multilobar
consolid
viral
pneumonia
develop
approxim
patient
undergon
lung
transplant
occur
time
follow
transplant
cmv
second
common
caus
pneumonia
patient
receiv
lung
transplant
common
opportunist
infect
opportunist
infect
repres
signific
viral
infect
usual
occur
month
transplant
primari
infect
seriou
form
observ
seroneg
patient
receiv
graft
seroposit
donor
patient
seroposit
secondari
cmv
infect
develop
reactiv
latent
diseas
follow
institut
immunosuppress
therapi
infect
differ
strain
cmv
infect
patient
may
asymptomat
may
develop
fulmin
pneumonia
possibl
extrathorac
find
retin
hepat
gastriti
present
symptom
includ
dyspnea
fever
cough
common
find
chest
radiograph
patient
cmv
infect
diffus
parenchym
hazi
ct
scan
find
includ
area
groundglass
attenu
reticul
multipl
small
illdefin
nodul
even
less
commonli
area
dens
consolid
diagnosi
cmv
pneumonia
made
bronchoscopi
lavag
biopsi
cytopath
chang
associ
cmv
infect
includ
cytomegali
multipl
small
basophil
cytoplasm
inclus
larg
nuclear
inclus
surround
halo
thicken
nuclear
membran
see
fig
prophylact
therapi
acyclovir
immun
globulin
reduc
incid
cmv
infect
patient
undergon
transplant
procedur
less
common
caus
viral
infect
includ
herp
simplex
viru
hsv
infect
patient
hsv
infect
present
fever
cough
dyspnea
demonstr
symptomat
improv
therapi
intraven
acyclovir
radiograph
find
may
absent
may
demonstr
diffus
groundglass
opac
histopatholog
classic
hsv
inclus
consist
dens
eosinophil
mass
within
nucleu
surround
clear
halo
peripher
margin
bead
nuclear
chromatin
hsv
may
form
multinucl
cell
opportunist
fungal
infect
less
common
viral
infect
associ
higher
mortal
fungal
pneumonia
usual
occur
day
follow
transplant
commonli
involv
transplant
lung
howev
also
involv
nativ
lung
singl
lung
transplant
case
especi
patient
copd
ct
imag
studi
commonli
reveal
combin
nodul
multipl
variabl
size
irregular
margin
consolid
groundglass
opacif
pleural
effus
also
common
case
gm
help
identifi
fungal
organ
howev
even
absenc
identifi
organ
gm
infect
might
consid
cultur
serolog
attempt
local
invas
dissemin
aspergillu
infect
account
posttransplant
infect
death
patient
undergo
lung
transplant
aspergillu
infect
commonli
character
local
invas
necrot
bronchial
anastomosi
ie
ulcer
tracheobronch
typic
occur
within
month
transplant
aspergillu
infect
involv
lung
parenchyma
tend
cavit
upperlob
predomin
histopatholog
hypha
aspergillu
sp
septat
branch
appear
uniform
grow
parallel
fashion
septa
regular
interv
branch
dichotom
usual
inhal
amphotericin
b
often
use
immedi
posttransplant
period
help
elimin
complic
patient
also
discharg
voriconazol
daili
prophylaxi
first
year
patient
undergon
lung
transplant
procedur
increas
suscept
p
jiroveci
infect
prophylaxi
trimethoprimsulfamethoxazol
effect
prevent
infect
incid
nearli
without
prophylaxi
incid
p
jiroveci
infect
approach
histolog
cyst
p
jiroveci
round
oval
measur
diamet
often
promin
groov
fold
p
jiroveci
pneumonia
classic
consist
intraalveolar
foami
exud
organ
appear
small
bubbl
background
proteinac
exud
although
varieti
reaction
occur
well
incid
ptld
significantli
higher
thorac
organ
transplant
compar
solidorgan
transplant
develop
lung
transplant
recipi
oppos
approxim
incid
solid
organ
recipi
ptld
present
allograft
adult
ptld
common
neoplasm
year
posttransplant
peak
month
posttransplant
children
lymphoma
far
common
posttransplant
malign
time
fact
ptld
major
caus
morbid
mortal
pediatr
lung
transplant
recipi
risk
factor
ptld
solid
organ
transplant
includ
patient
age
type
organ
transplant
ebv
infect
statu
host
transplant
immunosuppress
regimen
ptld
clinic
morpholog
molecularli
heterogen
spectrum
lymphoprolif
disord
rang
earli
ebvdriven
polyclon
polymorph
prolifer
infecti
mononucleosislik
ebvposit
ebvneg
monomorph
tumor
ptld
commonli
associ
ebv
infect
bcell
either
reactiv
latent
viru
primari
ebv
commonli
acquir
donor
organ
recent
studi
show
five
seven
lungtranspl
children
develop
ptld
ebvneg
recipi
receiv
ebvposit
lung
seri
heart
andor
lung
transplant
recipi
ptld
identifi
amongst
ptld
case
two
bcell
monoclon
polymorph
ptld
bcell
monomorph
ptld
see
fig
diffus
larg
bcell
lymphoma
dlbcl
two
burkitt
lymphoma
ebv
detect
patient
case
show
monoclon
igv
gene
rearrang
igv
somat
hypermut
found
case
indic
preval
origin
germin
centerexperienc
b
cell
given
associ
ebv
infect
ptld
elev
ebv
viral
load
measur
peripher
blood
propos
marker
develop
ptld
addit
monitor
degre
immunosuppress
diagnosi
ptld
immun
function
assay
immunosuppress
drug
level
may
aid
clinician
assess
risk
ptld
monitor
treatment
diagnosi
tcell
ptld
tend
occur
later
tend
associ
ebv
infect
tcell
ptld
associ
wors
prognosi
bcell
ptld
patient
ptld
may
asymptomat
may
nonspecif
complaint
fever
weight
loss
dyspnea
lethargi
solitari
multipl
pulmonari
nodul
rang
size
cm
common
pulmonari
manifest
patient
ptld
mediastin
hilar
adenopathi
also
observ
case
patient
present
solitari
pulmonari
nodul
better
overal
prognosi
howev
ptld
rapid
onset
predilect
extranod
site
aggress
clinic
behavior
poor
outcom
result
high
mortal
associ
ptld
treatment
often
pose
challeng
common
treatment
ptld
includ
decreas
immunosuppress
combin
surgic
resect
antivir
agent
radiat
chemotherapi
reduct
withdraw
immunosuppress
therapi
may
result
partial
complet
regress
ptld
higher
risk
graft
reject
associ
ptld
treatment
one
reason
need
earli
detect
diseas
adult
malign
remain
common
complic
lung
transplant
among
lung
transplant
survivor
malign
year
posttransplant
respect
although
lymphoprolif
disord
common
year
posttransplant
nonmelanoma
skin
malign
lead
malign
year
posttransplant
children
incid
posttransplant
malign
higher
adult
earli
transplant
children
develop
within
first
year
transplant
year
posttransplant
found
malign
time
posttransplant
lymphoma
far
common
posttransplant
malign
children
risk
cancer
higher
follow
lung
transplant
kidney
transplant
lung
transplant
patient
uniqu
characterist
baselin
genet
environment
background
immunosuppress
regimen
differ
patient
receiv
kidney
transplant
may
contribut
increas
risk
besid
nonmelanoma
skin
cancer
lymphoprolif
disord
malign
report
associ
solid
organ
transplant
includ
kaposi
sarcoma
anogenit
cancer
oral
caviti
malign
esophag
urinari
bladder
cancer
hepatocellular
carcinoma
sarcoma
acut
graft
vs
host
diseas
gvhd
uncommon
usual
fatal
complic
lung
transplant
effect
therapi
exist
among
ten
report
patient
eight
grade
acut
gvhd
die
within
day
one
recent
case
report
patient
grade
acut
gvhd
blt
success
treat
highdos
corticosteroid
basiliximab
extracorpor
photopheresi
unsuccess
day
patient
develop
low
grade
fever
chill
prurit
maculopapular
rash
chest
spread
proxim
extrem
next
day
liver
function
test
elev
skin
biopsi
show
dermal
inflamm
patchi
loss
basal
layer
vacuolar
degener
apoptosi
cell
necrosi
suggest
gvhd
day
later
profus
green
wateri
diarrhea
develop
abdomin
pain
paralyt
ileu
colonoscopi
show
ulcer
mucosa
destruct
intestin
crypt
featur
compat
gvhd
leucopenia
sever
anemia
deterior
liver
function
diagnosi
confirm
chimer
studi
reveal
recipientdonor
lymphocyt
ratio
second
case
acut
gvhd
lung
transplant
success
treat
corticosteroid
patient
present
mild
symptom
prurit
rash
blurri
vision
suggest
lowgrad
gvhd
diagnosi
confirm
small
dose
prednison
result
resolut
gvhd
within
week
lung
harvestreperfus
ischemiareperfus
ir
injuri
transplant
remain
common
caus
earli
posttransplant
respiratori
failur
manifest
typic
first
h
transplant
report
rate
great
mortal
patient
ir
injuri
compar
patient
without
ir
injuri
clinic
equival
ir
injuri
pgd
ishlt
work
group
pgd
propos
fourtier
grade
scheme
pgd
base
pf
ratio
radiolog
chest
infiltr
assess
time
point
h
h
reperfus
h
ir
injuri
usual
present
immedi
impair
lung
function
transplant
accompani
rapid
develop
pulmonari
edema
increas
pulmonari
vascular
resist
decreas
airway
complianc
patient
ir
injuri
requir
prolong
mechan
ventil
greater
hospit
stay
increas
risk
multiorgan
failur
lung
ir
injuri
longterm
consequ
risk
factor
late
graft
failur
ob
ir
injuri
occur
due
prolong
ischemia
transplant
ischem
injuri
pulmonari
vascular
endothelium
increas
permeabl
result
pulmonari
edema
histolog
ir
injuri
present
acut
lung
injuri
pattern
includ
dad
see
fig
perivascular
infiltr
usual
present
distinguish
acut
reject
howev
infect
present
similarli
need
exclud
stain
cultur
serolog
pathophysiolog
lung
ir
injuri
remain
incomplet
understood
lung
particularli
suscept
ir
injuri
like
owe
rich
vascular
rel
larg
surfac
area
bloodborn
compon
interact
endothelium
mechan
ir
injuri
divers
includ
gener
reactiv
oxygen
speci
ro
leukocyt
activationrecruit
complement
platelet
activ
abnorm
pulmonari
vascular
tone
increas
procoagul
activ
product
proinflammatori
cytokin
increas
consider
lung
ir
express
cytokin
lung
ir
may
caus
immedi
tissu
injuri
may
predispos
lung
allograft
reject
sever
studi
suggest
lung
ir
injuri
biphas
distinct
acut
injuri
character
macrophag
activ
follow
later
neutrophildepend
injuri
although
recurr
diseas
allograft
report
transplant
case
gener
clinic
signific
diseas
recurr
allograft
report
includ
giant
cell
interstiti
pneumonia
sarcoidosi
lymphangioleiomyomatosi
langerhan
cell
histiocytosi
allerg
bronchopulmonari
aspergillosi
desquam
interstiti
pneumonia
bronchioloalveolar
carcinoma
alveolar
proteinosi
diffus
pan
bronchiol
morpholog
featur
ident
diseas
nontranspl
lung
bronchial
dehisc
common
anastomot
airway
complic
earli
postop
period
occur
case
ischemia
anastomot
site
major
factor
develop
complic
dehisc
probabl
best
assess
bronchoscopi
howev
ct
scan
typic
demonstr
presenc
extralumin
ga
sensit
specif
dehisc
patient
telescop
anastomos
also
may
develop
small
anastomot
diverticula
appear
smooth
round
air
collect
inferiormedi
aspect
anastomosi
anastomot
strictur
occur
approxim
case
risk
stenosi
may
increas
telescop
anastomosi
stenos
often
manifest
progress
airflow
obstruct
difficult
differenti
caus
acut
reject
bo
strictur
probabl
best
evalu
bronchoscopi
howev
ct
scan
often
demonstr
area
narrow
treatment
stent
typic
expand
metal
stent
recent
balloon
dilat
obviat
need
stent
center
app
lung
transplant
singl
lung
transplant
slt
copd
aat
ipf
account
app
indic
slt
advantag
slt
blt
includ
technic
easier
procedur
shorter
surgeri
time
abil
transplant
two
patient
one
donor
howev
disadvantag
slt
instanc
surviv
rate
slt
blt
recipi
differ
diverg
obvious
later
year
transplant
surviv
slt
compar
blt
disadvantag
slt
includ
less
pulmonari
reserv
propens
complic
relat
residu
nativ
lung
nativ
lung
complic
previous
report
patient
may
associ
signific
morbid
mortal
may
partli
explain
outcom
slt
inferior
blt
recent
studi
report
occurr
pneumothorac
malign
aspergilloma
pneumonia
bronchopleur
fistula
pulmonari
embol
form
advanc
lung
diseas
includ
copd
ipf
associ
increas
risk
lung
cancer
complic
aris
nativ
lung
transplant
patient
also
often
structur
damag
nativ
lung
underli
diseas
process
increas
risk
complic
aspergilloma
pneumothorac
median
time
transplant
major
nativ
lung
complic
year
rang
year
one
studi
patient
nativ
lung
complic
die
thereof
median
posttranspl
surviv
lower
slt
recipi
signific
nativ
lung
complic
vs
year
p
nativ
lung
pneumonectomi
perform
patient
patient
nativ
lung
complic
trend
toward
improv
posttranspl
surviv
patient
underw
nativ
lung
pneumonectomi
compar
undergo
pneumonectomi
howev
differ
surviv
patient
underw
nativ
lung
pneumonectomi
nativ
lung
complic
major
patient
ob
also
sever
bronchiectasi
specimen
bronchogram
bronchial
tree
show
altern
area
dilat
constrict
microscop
bronchiectasi
may
associ
area
mucou
plug
goblet
cell
hyperplasia
squamou
metaplasia
denud
bronchial
epithelium
submucos
scar
acut
chronic
inflamm
bronchial
wall
occasion
foreign
bodi
giant
cell
present
probabl
repres
manifest
aspir
obliter
termin
respiratori
bronchiol
often
observ
distal
area
bronchiectasi
lung
allograft
probabl
result
sever
factor
includ
immunerel
injuri
infect
mucostasi
aspir
loss
innerv
despit
advanc
oper
manag
lung
preserv
critic
care
immunosuppress
longterm
surviv
lung
transplant
remain
limit
fact
outcom
lung
transplant
worst
solid
organ
transplant
main
obstacl
present
day
lung
transplant
involv
lack
donor
organ
ir
injuri
acut
reject
develop
ob
increas
suscept
lung
injuri
infect
constant
environment
exposur
local
innat
immun
activ
like
contribut
high
rate
reject
ishlt
registri
report
surviv
rate
surviv
rate
mortal
highest
first
year
consist
decreas
across
subsequ
time
period
see
tabl
first
day
graft
failur
noncmv
infect
cardiovascular
complic
technic
problem
account
mortal
first
year
bo
noncmv
infect
predomin
caus
death
year
malign
cardiovascular
caus
account
almost
report
caus
death
howev
compar
data
begin
overal
surviv
consist
improv
era
improv
surviv
larg
due
improv
year
surviv
long
term
surviv
improv
well
although
seemingli
lesser
degre
evid
suggest
age
pretranspl
diagnosi
donor
cmv
statu
play
import
prognost
role
instanc
surviv
halflif
patient
older
year
age
year
compar
year
age
overal
surviv
rate
month
transplant
lowest
ipf
ipah
highest
cf
copd
like
due
differ
earli
complic
includ
pgd
cmv
seroposit
donor
associ
wors
surviv
howev
underli
reason
associ
entir
clear
induc
state
immun
suppress
key
success
clinic
lung
transplant
immunosuppress
regimen
use
lung
transplant
base
success
protocol
evolv
renal
heart
transplant
posttransplant
morbid
see
tabl
present
year
commonli
caus
exacerb
immunosuppress
medicin
includ
hypertens
renal
dysfunct
dyslipidemia
bo
malign
common
posttransplant
morbid
instanc
bo
develop
patient
year
transplant
year
howev
surviv
patient
report
activ
limit
year
time
point
furthermor
survivor
report
least
one
malign
year
transplant
affect
malign
year
surviv
pediatr
lung
transplant
similar
report
adult
median
surviv
year
period
result
clearli
improv
one
surviv
rate
pediatr
recipi
transplant
recent
era
respect
compar
recipi
transplant
graft
failur
technic
issu
cardiovascular
failur
infect
common
caus
pediatr
death
earli
posttranspl
period
wherea
infect
graft
failur
bo
common
caus
late
death
preval
bo
steadili
increas
time
posttransplant
expect
cumul
incid
malign
also
increas
time
transplant
lymphoprolif
disord
make
great
major
report
malign
children
despit
complic
function
statu
great
major
longterm
pediatr
survivor
good
survivor
report
limit
activ
total
pediatr
retranspl
procedur
report
januari
june
major
procedur
perform
month
initi
transplant
surviv
period
slightli
poorer
primari
transplant
year
